My watch list  

84 Current news of High-Tech Gründerfonds Management


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
3D printer for medicine

Kumovis closes Series A funding led by Renolit and Solvay


Kumovis, the developer of the world’s first 3D printer with clean room integration, announced that it has raised a €3.6 million Series A funding round. In Renolit SE and Solvay Ventures, the Munich-based start-up has found two additional partners on its way to establish industrial additive ...


image description
€6 M to develop and launch a kit dedicated to sample preparation for single-cell RNA-sequencing

Paris-based biotechnology startup raises Series A financing


Scipio bioscience, a Paris-based biotechnology company, developing a new generation of single-cell sequencing solutions, announces that it has secured a €6.0 M Series A financing from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of ...


image description
Tyrolean virtual reality start-up receives seven-figure growth financing

Products tailored towards the Life Science industry


As a pioneer in education technology, Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the DeepTraining approach, implemented ...


image description
€11 Mio. for the treatment of acute and chronic liver diseases

HepaRegeniX secures Series B Financing


Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models. HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases announced the closing of its ...


Biograil secures seed funding for oral delivery device with potential to transform market for injectables


Biograil ApS, an innovative biotechnology company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a seed funding of 3 Million Euro (with potential to expand to 5 Million Euro). The investor Syndicate was led by the experienced ...


Cunesoft joins forces with Phlexglobal


The Munich-based Cunesoft GmbH, an provider of cloud-based intelligent regulatory data management software and services for the life sciences industry, announced that it has been acquired by Phlexglobal from current investors including Bayern Kapital, High-Tech Gründerfonds and ...


image description
Removal Of Tumor Cells From Surgical Blood

Over 5 Million Euros For Lindis Blood Care


As is standard during tumor surgeries, when large volumes of blood are lost, donor blood is given to the patient. Worldwide, this is the case for more than half a million tumor surgeries annually. This procedure can result in many serious side effects and increased tumor recurrence rates. ...


Biotech start-up Verovaccines concludes international pharma cooperation agreement

The goal is to develop and commercialize novel, cost-effective vaccines for animal health


The Verovaccines GmbH has signed the first cooperation agreement with a Japanese pharmaceutical partner for the joint development of an animal vaccine. This cooperation documents a significant step forward in the company’s development and the clear interest of market participants in vaccines ...


image description
Genomic methods and big-data to contain the illegal animal trade

Ark-Biodiversity and HTGF have completed the first joint financing round


Ark-Biodiversity is the newest foundation of the serial entrepreneur Alexander Olek. The 50-year-old father of four children says: “I don’t believe in the survival of humanity without biodiversity; and I do not believe in the conservation of biodiversity, unless our societies find joint ...


image description
€12M Series A Financing to Develop Novel Immuno-Virotherapies Against Cancer


Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...


Page 1 From 9
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE